AUS
NZ
UK
CA
USA
IND
Highlights
- New lab results unveiled for HMBD‑002 in TNBC
- Focus on VISTA as an immune system target
- Broader research underway for multiple cancers
Percheron Therapeutics Ltd (ASX:PER) has shared new laboratory results on its investigational therapy HMBD‑002, aimed at triple‑negative breast cancer (TNBC) — an aggressive form of breast cancer that remains a major medical challenge. While not currently a part of the top ASX 100, this development reflects an important step forward in cancer research.
Understanding TNBC and Its Treatment Gap
Triple‑negative breast cancer accounts for a notable share of breast cancer cases and is known for its resistance to many existing treatment options. Current therapies often fall short in addressing this condition, leaving a significant need for new approaches.
Research has identified VISTA — a protein that can suppress the immune system — as being present in a considerable proportion of TNBC cases. By targeting VISTA, researchers aim to improve the body’s ability to control tumour growth.
HMBD‑002 and the New Findings
The latest preclinical studies, carried out in animal models, show that HMBD‑002 can help block tumour development in TNBC cases where VISTA is highly expressed. The research also indicates that this therapy might work through more than one pathway — not only influencing immune checkpoints but also interacting with growth signals. This dual approach could potentially make it suitable for patients who have not responded to other immunotherapy treatments.
In addition to TNBC, HMBD‑002 has been explored in combination with radiotherapy for other cancers, including squamous cell carcinoma of the head and neck. These broader studies add weight to its potential role as a versatile cancer therapy candidate.
Next Steps in Development
With the current laboratory results in hand, further clinical investigations are planned to assess HMBD‑002 in people with advanced cancers, particularly those whose tumours display high VISTA expression. The goal will be to determine its safety profile and explore its use in different cancer settings.
As research progresses, collaboration between scientists and clinicians will help shape how HMBD‑002 could fit into the future of cancer treatment strategies.
Frequently Asked Questions
- What is HMBD‑002?
A laboratory‑developed therapy being researched for its ability to target immune suppression in certain cancers, including TNBC. - What makes TNBC challenging to treat?
It does not respond well to many standard therapies, and options for targeted treatment are limited. - Why is VISTA important in this research?
VISTA is a protein that can help tumours evade immune detection, making it a key target for new treatments.
